alectinib 150mg cap
| Product Overview | |
| Generic Name | alectinib 150mg cap |
| Brand Name(s) | Alecensa® |
| Form | Hard capsules; oral use |
| Strength | 150 mg |
| Therapeutic Class | Antineoplastic agent; kinase inhibitor (ALK inhibitor) |
| ATC Code | L01ED03 |
| Manufacturing & Regulatory | |
| Manufacturer | Roche group / Genentech |
| Country | confirmed from pack, batch documents, CoA |
| GMP Compliance | WHO-GMP, EU-GMP |
| COFEPRIS | 010.000.6227.00 |
| Free Sale Certificate | must be requested from the manufacturer |
| Logistics & Export | |
| MOQ | 10 Units |
| Shelf Life | 60 months |
| Storage | Do not store above 30°C |
| Incoterms | EXW |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | For institutional supply, request batch CoA |
| SDS | Genentech/Roche publishes an SDS for ALECENSA |
| CTD Summary | CTD/eCTD Modules 2–5 are proprietary and normally not provided freely |
Description
An oral ALK tyrosine kinase inhibitor used for adults with ALK-positive non-small cell lung cancer. It is indicated for metastatic ALK-positive NSCLC
